Filter posts

Watchdog Report Reaffirms Concerns With Fail First

A new report by the Office of Inspector General at the U.S. Department of Health …

Bloomberg Exposes How Drug Cost Middlemen “Rake in Millions”

Bloomberg has authored an investigative piece exposing drug cost middlemen, better known as pharmacy benefit …

Hits to Patients Keep on Coming

At a time when prescription drug prices and spending are remarkably stable, patients are getting …

PBS NewsHour: Why a Patient Paid a $285 Copay for a $40 Drug

A featured story by PBS NewsHour reaffirms that insurance companies and drug cost middlemen determine …

As Out-of-Pocket Costs Rise, Insurers Spend Big on Administrative Costs

It seems every week the insurance industry is busy pointing the finger at biopharmaceutical innovators …

Debunking a Common Myth on Out-of-Pocket Costs

The facts continue to show that, when it comes to prescription drug costs, the country …

Co-Pay Accumulator Programs Are a Bad Deal for Patients

As we see time and time again, health insurance providers and pharmacy benefit managers (PBMs) …

New Report Offers “Distorted View” of Biopharma Industry

This week, the Minority Staff of the U.S. Senate Committee on Finance released a report …

Drug Importation and Its Dangerous Side Effects

Writing for the National Review, Sally Pipes of the Pacific Research Institute authors a stark …

BIO Communications Responds to Misleading Op-Ed about Medicaid Drug Costs

This week, Dr. Peter Bach of Memorial Sloan-Kettering Cancer Center authored an op-ed about the …